EUVIMEDOpdag EUVIMED
Leserbrief

Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis

Richard C De Vuyst iD, Erin Bennard, Charissa W Kam iD, Cameron J McKinzie iD, Charles R Esther iD

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26334 ↗

At a glance

Leserbrief in Pediatric Pulmonology, 2023. Written by Richard C De Vuyst and 4 co-authors. Institution: Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Major MEDLINE topics: Cystic Fibrosis. Cited 21 times so far (Crossref); 6 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in a fraction of treated individuals, indicating an ongoing need to optimize other treatments in a subset of patients.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisHumansPyridinesCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesMutationChloride Channel AgonistsDrug CombinationsPyrazolesPyrrolidinesQuinolonesIndoles

Substances

PyridinesCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesChloride Channel AgonistsDrug CombinationselexacaftorPyrazolesPyrrolidinesivacaftor

Authors and institutions

  • Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.

ORCID profiles: Richard C De Vuyst, Charissa W Kam, Cameron J McKinzie, Charles R Esther

Cite

APA

De Vuyst, R. C., Bennard, E., Kam, C. W., McKinzie, C. J., & Esther, C. R. (2023). Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26334

Vancouver

De Vuyst RC, Bennard E, Kam CW, McKinzie CJ, Esther CR. Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26334

BibTeX
@article{DeVuyst2023,
  author = {De Vuyst, Richard C and Bennard, Erin and Kam, Charissa W and McKinzie, Cameron J and Esther, Charles R},
  title = {Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26334}
}
Start for free →